FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph...
What is the potential market size and competitive landscape for a Behçet's disease therapy, and how could that impact long-term revenue forecasts?
What is the expected timeline for FDA approval and market launch of SGX945, and how might that influence investor sentiment?
How will the orphan drug designation affect Soligenix's valuation and short-term stock movement?
13 days ago